Literature DB >> 9712588

Cerebral sinus thrombosis and oral contraceptives. There are limits to predictability.

J P Vandenbroucke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9712588      PMCID： PMC1113747          DOI： 10.1136/bmj.317.7157.483

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.

Authors:  J Rosing; G Tans; G A Nicolaes; M C Thomassen; R van Oerle; P M van der Ploeg; P Heijnen; K Hamulyak; H C Hemker
Journal:  Br J Haematol       Date:  1997-04       Impact factor: 6.998

Review 2.  Science, medicine, and the future: assessing thrombotic risk.

Authors:  M Laffan; E Tuddenham
Journal:  BMJ       Date:  1998-08-22

3.  Venous thrombosis--the interaction of genes and environment.

Authors:  R M Bertina; F R Rosendaal
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

4.  Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice.

Authors:  J R Meinardi; C M Henkens; M P Heringa; J van der Meer
Journal:  Blood Coagul Fibrinolysis       Date:  1997-03       Impact factor: 1.276

5.  Oral contraceptives and venous thromboembolism.

Authors:  G D Lowe; A Rumley; M Woodward; E Reid
Journal:  Lancet       Date:  1997-05-31       Impact factor: 79.321

6.  Resistance to activated protein C is reduced in women using oral contraceptives.

Authors:  B Osterud; R Robertsen; G B Asvang; F Thijssen
Journal:  Blood Coagul Fibrinolysis       Date:  1994-10       Impact factor: 1.276

7.  Apolipoproteins and ischaemic heart disease: implications for screening.

Authors:  N J Wald; M Law; H C Watt; T Wu; A Bailey; A M Johnson; W Y Craig; T B Ledue; J E Haddow
Journal:  Lancet       Date:  1994-01-08       Impact factor: 79.321

8.  [Public health economic evaluation of screening for APC resistance (Leiden mutation) in new oral contraceptive users].

Authors:  T Szucs; D Osterkorn; W Schramm
Journal:  Med Klin (Munich)       Date:  1996-05-15

Review 9.  Factor V Leiden: should we screen oral contraceptive users and pregnant women?

Authors:  J P Vandenbroucke; F J van der Meer; F M Helmerhorst; F R Rosendaal
Journal:  BMJ       Date:  1996-11-02

10.  High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.

Authors:  I Martinelli; E Sacchi; G Landi; E Taioli; F Duca; P M Mannucci
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245
View more
  3 in total

Review 1.  Cerebral venous sinus thrombosis.

Authors:  H Allroggen; R J Abbott
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

2.  Cerebral venous thrombosis: role of CT, MRI and MRA in the emergency setting.

Authors:  L Rizzo; S Greco Crasto; R Rudà; G Gallo; E Tola; D Garabello; R De Lucchi
Journal:  Radiol Med       Date:  2010-01-20       Impact factor: 3.469

3.  Rare Presentation of Cerebral Venous Sinus Thrombosis in a Child.

Authors:  Amar Taksande; Rewat Meshram; Purnima Yadav; Amol Lohakare
Journal:  J Pediatr Neurosci       Date:  2017 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.